Administration of lorcaserin to individuals with renal impairment

New Zealand Patent

APP PUB NO NZ-630494-A
SERIAL NO

63049411

Stats

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is the use of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin) for weight management, decreasing food intake, and inducing satiety in a therapeutic setting with consideration of the patient’s renal function. It has been determined that patients with severe renal impairment or end stage renal disease (ESRD) are exposed to greater levels of lorcaserin metabolites following administration of the agent and so the use of lorcaserin in these patients appears to be contraindicated. Further provided are low dose formulations of lorcaserin.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ARENA PHARM INCNot Provided

International Classification(s)

Inventor(s)

Inventor Name Address
ANDERSON CHRISTEN M -
SHANAHAN WILLIAM R -

Cited Art Landscape

Load Citation